Searchable abstracts of presentations at key conferences in endocrinology

ea0084ps3-12-108 | Graves’ Disease 2 and Orbitopathy | ETA2022

The incidence and risk factors of radioiodine-induced graves’ disease following treatment of thyroid autonomous tissue

Zaletel Tjaša , Rot Živa , Krkovic Danijela , Gaberscek Simona , Zaletel Katja

Introduction: Radioiodine (I-131) therapy is an effective treatment for thyroid autonomy but may induce Graves’ disease (GD) but in up to 5% of patients. GD is characterised by antibodies against TSH receptor (TSHRAb). We set out to evaluate the incidence and risk factors of I-131-induced GD in patients with thyroid autonomy treated with I-131.Methods: We retrospectively reviewed patients with solitary toxic adenoma or toxic nodular goiter who were ...

ea0092ps2-15-06 | Hyperthyroidism | ETA2023

Factors influencing early outcome of radioiodine treatment in patients with graves’ disease

Pirnat Edvard , Zaletel Tjaša , Rot Živa , Gaberscek Simona , Zaletel Katja

Aim: In Graves’ disease (GD) the goal of radioiodine (I-131) application is the elimination of hyperthyroidism. The reported success rate 1 year after treatment is up to 90%. The aim of this retrospective study was to assess the factors influencing the early outcome 3 months after I-131 treatment of GD patients in an iodine sufficient area.Materials and Methods: We reviewed medical records of GD patients who received I-131 therapy between January 20...